Policy Notices

• Special Emphasis Notice (SEN): AHRQ Announces Interest in Health Services Research to Address Substance Use Disorder Epidemic
  (NOT-HS-21-010)
  Agency for Healthcare Research and Quality
  

• Announcement of Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows
  (NOT-OD-21-069)
  National Institutes of Health
  

General Notices

• Notice of Technical Assistance Webinar for Notice of Special Interest (NOSI): Small Business Initiatives for Innovative Diagnostic Technology for Improving Outcomes for Maternal Health
  (NOT-EB-21-007)
  National Institute of Biomedical Imaging and Bioengineering
  

• Notice Announcing NHGRI Guidance for Third-Party Involvement in Extramural Research
  (NOT-HG-21-023)
  National Human Genome Research Institute
  

• Request for Information (RFI): Inviting Comments and Suggestions to Advance and Strengthen Racial Equity, Diversity, and Inclusion in the Biomedical Research Workforce and Advance Health Disparities and Health Equity Research
  (NOT-OD-21-066)
  National Institutes of Health
  

Notice of Changes to Funding Opportunities

• Notice of NIDDK Participation in PAR-19-343 "Maximizing Opportunities for Scientific and Academic Independent Careers (MOSAIC) Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)"
  (NOT-DK-21-012)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Change to Key Dates for PAR-21-059 "Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)"
  (NOT-NS-21-045)
  National Institute of Neurological Disorders and Stroke
  

Notices of Special Interest

• Notice of Special Interest (NOSI): Administrative Supplements for Research on Womens Health in the IDeA States
  (NOT-GM-21-018)
  National Institute of General Medical Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute of Allergy and Infectious Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  National Institute of Nursing Research
  Office of Disease Prevention
  Office of Research on Women's Health
  

• Notice of Special Interest (NOSI): Urgent Competitive Revisions to IDeA and NARCH Programs to Address SARS-CoV-2 Vaccine Hesitancy
  (NOT-GM-21-021)
  National Institute of General Medical Sciences
  

• Notice of Special Interest (NOSI): Multi-Level HIV Prevention Interventions for Individuals at the Highest Risk of HIV Infection
  (NOT-MD-21-014)
  National Institute on Minority Health and Health Disparities
  National Institute on Drug Abuse
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI): Promoting Viral Suppression among Individuals from Health Disparity Populations Engaged in HIV Care
  (NOT-MD-21-015)
  National Institute on Minority Health and Health Disparities
  National Institute on Drug Abuse
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI) in Reducing Suicide Risk in Young People in Low- and Middle-Income Countries and Low-Resource Settings
  (NOT-MH-21-090)
  National Institute of Mental Health
  

• Notice of Special Interest: Advancing Health Communication Research on HIV Prevention, Treatment and Cure
  (NOT-MH-21-105)
  National Institute of Mental Health
  

• Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace
  (NOT-MH-21-125)
  National Institute of Mental Health
  National Center for Complementary and Integrative Health
  National Eye Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Neurological Disorders and Stroke
  

• Notice of Special Interest (NOSI): Availability of Administrative Supplements for Childcare Costs for Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellows
  (NOT-OD-21-070)
  National Institutes of Health
  John E. Fogarty International Center
  National Center for Advancing Translational Sciences
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Eye Institute
  National Human Genome Research Institute
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Allergy and Infectious Diseases
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute on Deafness and Other Communication Disorders
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  National Institute of Environmental Health Sciences
  National Institute of General Medical Sciences
  National Institute of Mental Health
  National Institute on Minority Health and Health Disparities
  National Institute of Neurological Disorders and Stroke
  National Institute of Nursing Research
  National Library of Medicine
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Dietary Supplements
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Office of Research on Women's Health
  

Funding Opportunities

• Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (Collaborative R01 Clinical Trial Required)
  (PAR-21-129)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• Clinical Trials to Test the Effectiveness of Treatment, Preventive, and Services Interventions (R01 Clinical Trial Required)
  (PAR-21-130)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
  
  

• Pilot Effectiveness Trials for Treatment, Preventive and Services Interventions (R34 Clinical Trial Required)
  (PAR-21-131)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• Confirmatory Efficacy Clinical Trials of Non-Pharmacological Interventions for Mental Disorders (R01 Clinical Trial Required)
  (PAR-21-132)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Devices for Psychiatric Disorders (U01 Clinical Trial Required)
  (PAR-21-133)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date
  
  

• Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R33 Clinical Trial Required)
  (PAR-21-134)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• Development of Psychosocial Therapeutic and Preventive Interventions for Mental Disorders (R61/R33 Clinical Trial Required)
  (PAR-21-135)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R33- Clinical Trial Required)
  (PAR-21-136)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• Early Stage Testing of Pharmacologic or Device-based Interventions for the Treatment of Mental Disorders (R61/R33 Clinical Trial Required)
  (PAR-21-137)
  National Institute of Mental Health
  Application Receipt Date(s): June 15, 2021, October 15, 2021February 15, 2022,June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024, June 15, 2021, October 15, 2021, February 15, 2022, June 15, 2022, October 14, 2022, February 15, 2023, June 15, 2023, October 17, 2023, February 15, 2024
  
  

• AD/ADRD Clinical Trials Short Course (R25 Independent Clinical Trial Not Allowed)
  (PAR-21-141)
  National Institute on Aging
  Application Receipt Date(s): May 25, 2021; May 25, 2022; May 25, 2023
  
  

• Triadic Interactions in Clinical Encounters Involving People with Alzheimer's Disease and Alzheimer's Disease-Related Dementias (AD/ADRD), Clinicians, and Care Partners (R01 Clinical Trial Optional)
  (RFA-AG-22-020)
  National Institute on Aging
  Application Receipt Date(s): June 23, 2021
  
  

• Data Standards for Tobacco Research and Scientific Review Program (U24) Clinical Trial Not Allowed
  (RFA-FD-22-002)
  Food and Drug Administration
  Application Receipt Date(s): June 1, 2021, by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.